Needham analyst Gil Blum has maintained their bearish stance on SRPT stock, giving a Sell rating on July 30.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gil Blum has given his Sell rating due to a combination of factors impacting Sarepta Therapeutics. The company’s earnings per share for the second quarter of 2025 exceeded expectations, primarily due to a significant milestone payment from Roche, rather than sustainable revenue growth. This raises concerns about the reliability of future earnings, especially as Sarepta did not provide any sales guidance.
Additionally, there is ongoing uncertainty surrounding the future revenues of Elevidys, particularly with the risks associated with upcoming study results that could affect the PMO franchise. The company’s financial outlook is further complicated by its high expected operational expenses starting in 2026, following a recent restructuring. These elements contribute to the cautious stance and the Sell rating issued by Gil Blum.
In another report released on July 30, Citi also maintained a Sell rating on the stock with a $12.00 price target.